Patents by Inventor Peter Wardman
Peter Wardman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090202571Abstract: A compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: —Ar is a substituted heteroaryl group bearing at least one nitro or azido group or is a benzoquinone, naphthoquinone or fused heterocyloquinone; -R1 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; -R2 is a glycoside, OH, optionally substituted alkyl, optionally substituted alkoxy, C2-C8 alkenyl, C1-C8 hydroxyalkyl, optionally substituted arylamino, optionally substituted aryl C1-C4 alkylamino or hydroxyalkylamino; and -R3 and R4 are each independently H or halo.Type: ApplicationFiled: September 26, 2005Publication date: August 13, 2009Applicants: HOPNIC LABORATORY CO., LTD., DAISO CO.,LTD.Inventors: Peter David Davis, Matthew Alexander Naylor, Peter Thomson, Steven Albert Everett, Michael Richard Lacey Stratford, Peter Wardman
-
Publication number: 20090137687Abstract: This invention relates to novel tricyclic quinone and catechol compositions, compositions containing prodrugs of tricyclic quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. In certain aspects, the compositions of the invention are capable of generating both a vascular targeting effect and tumor cell cytotoxicity (e.g., by oxidative stress) in order to achieve an enhanced anti-tumor response in a patient.Type: ApplicationFiled: June 19, 2008Publication date: May 28, 2009Applicants: OXiGENE, Inc., Baylor UniversityInventors: David Chaplin, Kevin G. Pinney, Peter Wardman, Vani P. Mocharla, Lisa K. Folkes
-
Publication number: 20080145372Abstract: The present invention relates to a compound of formula (1), or a pharmaceutically acceptable salt thereof, Formula: (1); wherein: R1 is a substituted aryl or heteroaryl group bearing at least one nitro or azido group or is an optionally substituted benzoquinone, optionally substituted naphthoquinone or optionally substituted fused heterocycloquinone: R2 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, aryl or heteroaryl; and R3 is selected such that R3NH2 represents a cytotoxic nucleoside analogue or an ester or phosphate ester prodrug of a cytotoxic nucleoside analogue, with the proviso that if R1 is an aryl group then R2 is not H.Type: ApplicationFiled: September 26, 2005Publication date: June 19, 2008Applicants: ANGIOGENE, PHARMACEUTICALS LIMITED, THE GRAY LABORATORY CANCER RESEARCH TRUSTInventors: Peter David Davis, Matthew Alexander Naylor, Peter Thomson, Steven Albert Everett, Michael Richard Lacey Stratford, Peter Wardman
-
Publication number: 20070099871Abstract: The present invention relates to a compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: Ar is a substituted aryl or heteroaryl group bearing at least one nitro or azido group or is a group of formula (2) or (3) wherein R1, and R2, which may be the same or different are independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, aryl, COR3 or, together with the intervening carbon atom, form an optionally substituted heterocycloalkyl or carbocyclic ring; L is —OC(O)— or —OP(O)(OR6)—; n is 0 or 1; X is 0, S, NR7 or a single covalent bond; R3 is OR4 or NR4R5; R4, R5, R6 and R7 are each independently hydrogen or optionally substituted alkyl or, where Rr is NR4R5, R4 and R5 can be joined to form, together with the intervening nitrogen atom, a heterocycloalkyl ring; R8 is hydrogen, alkoxy or dialkylaminoalkyl; R9 is optionally substituted alkyl; Rio is hydrogen, alkyl, alkoxy or dialkylaminoalkyl; R11 and R12 are independently hydrogen, alkyType: ApplicationFiled: March 26, 2004Publication date: May 3, 2007Applicants: ANGIOGENE PHARMACEUTICALS LIMITED, GRAY LABORATORY CANCER RESEARCH TRUSTInventors: Peter Davis, Matthew Naylor, Peter Thomson, Steven Everett, Michael Stratford, Peter Wardman
-
Publication number: 20060223827Abstract: A compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein Ar is a substituted heteroaryl group bearing at least one nitro or azido group or is a group of formula (2) or (3); R1 is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; R2 is alkyl, alkoxy, thialkoxy or halo; R3, R4 and R5 are each independently alkyl, alkoxy, thialkoxy or halo with the proviso that at least two of R3, R4 or R5 are alkoxy; L is —OC(O)— or —OP(O)(OR6)—; n is 0 or 1; X is O, S or NR7; Y is hydrogen, alkyl, alkoxy, thialkoxy, halo, hydroxy or dihydrogenphosphate; R6 is hydrogen or alkyl; R7 is hydrogen or alkyl; R8 is hydrogen, alkoxy or dialkylaminoalkyl; R9 is optionally substituted alkyl; R10 is hydrogen, alkyl, alkoxy or dialkylaminoalkyl; R11, and R12 are independently hydrogen, alkyl, alkoxy, thialkoxy, amono alkylamino, dialkylamino, morpholino, alkylmorpholino, piperidino, alkylpiperidiono, piperazino, alkylpiperazino or 1-aziridinyl; and A, togetheType: ApplicationFiled: March 26, 2004Publication date: October 5, 2006Inventors: Peter Davis, Matthew Naylor, Peter Thomson, Steven Everett, Michael Stratford, Peter Wardman
-
Publication number: 20060133996Abstract: The present invention provides a method and apparatus for measuring the effectiveness of a sunscreen composition or other skin preparation in reducing the exposure of human skin to UVA radiation, wherein differential electron spin resonance spectroscopy is used to quantify the extent of UVA-induced ascorbate or other measurable radical production in the shielded skin, in comparison with reference, preferably unshielded, skin.Type: ApplicationFiled: October 28, 2003Publication date: June 22, 2006Inventors: Rachel Haywood, Peter Wardman, Roy Sanders, Claire Linge
-
Publication number: 20050203166Abstract: Compounds of formula (I), or physiologically functional derivatives thereof, wherein: R1, R2, R3 and R?3 are independently selected from H or lower alkyl; and R4, R5, R6 and R7 are independently selected from H, electron withdrawing groups (such as F, Cl, Br, I, OCF3, carboxyl groups, acetal groups, electron deficient aryl groups), lower alkyl groups, lower alkoxy groups, aryl groups or aryloxy groups, wherein at least one of R4, R5, R6 and R7 is selected from an electron withdrawing group, may be used in methods of therapy, particular in treating neoplastic diseases in methods of GDEPT, ADPET, PDEPT and PDT.Type: ApplicationFiled: May 9, 2005Publication date: September 15, 2005Inventors: Peter Wardman, Lisa Folkes, Gabriele Dachs, Sharon Rossiter, Olga Greco
-
Patent number: 6890948Abstract: Compounds of formula (I), or physiologically functional derivatives thereof, wherein: R1, R2, R3 and R?3 are independently selected from II or lower alkyl; and R4, R5, R6 and R7 are independently selected from H, electron withdrawing groups (such as F, Cl, Br, I, OCF3, carboxyl groups, acetal groups, electron deficient aryl groups), lower alkyl groups lower alkoxy groups, aryl groups or aryloxy groups, wherein it least one of R4, R5, R6, and R7 is selected from an electron withdrawing group, may be used in methods of therapy, particular in treating neoplastic diseases in methods of GDEPT, ADPET, PDEPT and PDTType: GrantFiled: June 28, 2001Date of Patent: May 10, 2005Assignee: Cancer Research Technology LimitedInventors: Peter Wardman, Lisa Folkes, Gabriele U. Dachs, Sharon Rossiter, Olga Greco
-
Patent number: 6531097Abstract: A system for measuring the concentration of an assay substance comprising a sensor having an optical fiber (10) on one end of which is coated a body (22). A fluorophor is dispersed within the body (22), the fluorescent activity of which is altered in relationship to the concentration of the assay substance. Light from a source such as an LED (40) is carried by the fiber (10) to the body (22). Light emitted by the fluorophor is carried to a detector unit (54) along the fiber (10). Concentration of the assay substance is determined by measurement of the characteristics of the growth in emitted light following activation of the LED (40).Type: GrantFiled: April 27, 2000Date of Patent: March 11, 2003Assignee: Cancer Research Campaign Technology, Ltd.Inventors: Borivoj Vojnovic, William K. Young, Peter Wardman